Dr. Rebecca E. Cagnina, MD

Dr. Cagnina practices at Boston Children's Hospital in Boston, Massachusetts, part of The Children's Hospital.

Dr. Cagnina's NPI, 1275857807, was assigned on March 25, 2010. Dr. Cagnina graduated from University of Virginia School of Medicine in 2010. Dr. Cagnina holds Massachusetts license 277326.

Dr. Cagnina's primary practice is Boston Children's Hospital, at 300 Longwood Avenue, Boston, MA 02115 in Suffolk County. The practice phone is (617) 735-6000.

Dr. Cagnina's primary practice is Boston Children's Hospital in Boston, Massachusetts, part of The Children's Hospital. Dr. Cagnina is also affiliated with Massachusetts General Hospital. The medical group on file is Brigham and Women's Hospital. Dmand AI also links Dr. Cagnina to 3 more hospitals, 3 medical groups and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cagnina practices, 6 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Cagnina's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Cagnina is licensed in Massachusetts.

CMS data shows 184 Medicare services from Dr. Cagnina across 8 procedure codes in 2024, for 161 Medicare patients. Medicare paid $8,050 for them.

CMS counts 161 Medicare patients who saw Dr. Cagnina in 2024. The largest group is 75 to 84, with 68 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cagnina's median patient age at 57, with 63% women.

In 2024, Dr. Cagnina wrote 99 Medicare Part D claims for 13 patients. 65% of them were for generic drugs. CMS names the drug for 45 of them, across 3 drugs with 11 or more claims each, at $467,043 in total drug cost. In 2023, CMS named 18 claims across 1 drug.

Dr. Cagnina accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cagnina as offering telehealth.

Dmand AI links 15 papers to Dr. Cagnina, published from 2011 to 2025. 2016 was the busiest year, with 2. The most frequent topics are Inflammation, Lung and Macrophages. Dr. Cagnina has published most often in Am J Respir Crit Care Med. Dr. Cagnina's most frequent co-authors are Borna Mehrad, MD, Bruce David Levy, MD and Ahmet Z. Uluer, DO.

Dmand AI links Dr. Cagnina to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Cystic Fibrosis and Infant, Newborn, Diseases. National Jewish Health sponsors the most, 2.

CMS Open Payments shows 6 general payments to Dr. Cagnina from 5 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 91% of the total. Genentech, Inc. paid the most, $1,000.

Dr. Cagnina graduated from University of Virginia School of Medicine in 2010.